Assembly of Human Organs from Stem Cells to Study Liver Disease  by Handa, Kan et al.
The American Journal of Pathology, Vol. 184, No. 2, February 2014
AS
IP
20
14
AJ
P
CM
E P
rog
ramajp.amjpathol.orgLiver Pathobiology Theme IssueREVIEW
Assembly of Human Organs from Stem Cells to Study Liver
Disease
Kan Handa,*y Kentaro Matsubara,*y Ken Fukumitsu,*z Jorge Guzman-Lepe,*y Alicia Watson,* and Alejandro Soto-Gutierrez*yFrom the Department of Pathology* and the Transplantation Section,y Children’s Hospital of Pittsburgh, Thomas E. Starzl Transplantation Institute and
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; and the Division of Hepato-Biliary-Pancreatic and
Transplant Surgery,z the Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
CME Accreditation Statement: This activity (“ASIP 2014 AJP CME Program in Pathogenesis”) has been planned and implemented in accordance with the Essential Areas and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the
American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this journal-based CME activity (“ASIP 2014 AJP CME Program in Pathogenesis”) for a maximum of 48 AMA PRA Category 1 Credit(s). Physicians should
only claim credit commensurate with the extent of their participation in the activity.
CME Disclosures: The authors of this article and the planning committee members and staff have no relevant ﬁnancial relationships with commercial interests to disclose.Accepted for publicationC
P
hNovember 18, 2013.
Address correspondence to
Alejandro Soto-Gutierrez,
M.D., Ph.D., Department of
Pathology, University of Pitts-
burgh, 3511 Rangos Research
Bldg, 530 45th St, Pittsburgh,
PA 15201. E-mail:
sotogutierreza@upmc.edu.opyright ª 2014 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.11.003Recently, signiﬁcant developments in the ﬁeld of liver tissue engineering have raised new possibilities for
the study of complex physiological and pathophysiological processes in vitro, as well as the potential to
assemble entire organs for transplantation. Human-induced pluripotent stem cells have been differen-
tiated into relatively functional populations of hepatic cells, and novel techniques to generate whole
organ acellular three-dimensional scaffolds have been developed. In this review, we highlight the most
recent advances in organ assembly regarding the development of liver tissue in vitro. We emphasize
applications that involve multiple types of cells with a biomimetic spatial organization for which three-
dimensional conﬁgurations could be used for drug development or to explain mechanisms of disease. We
also discuss applications of liver organotypic surrogates and the challenges of translating the highly
promising new ﬁeld of tissue engineering into a proven platform for predicting drug metabolism and
toxicity. (Am J Pathol 2014, 184: 348e357; http://dx.doi.org/10.1016/j.ajpath.2013.11.003)Supported by NIH grants DK083556 (A.S.-G.) and EB0010216 (A.W.),
an American Society of Transplantation Basic Science Faculty Develop-
ment grant (A.S.-G.), and the Competitive Medical Research Fund of the
University of Pittsburgh Medical Center Health System grant (A.S.-G.).
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This article is part of a review series on liver pathobiology.The ﬁeld of liver regenerative medicine is composed of a
broad range of approaches, including cell therapy, immu-
nomodulation therapy, and liver tissue engineering. These
approaches are aimed toward replacing or regenerating tissue
to restore functionality in failing livers.1e6 Some of these
technologies have also been used as tools to model human
liver disease and predict drug toxicity and response.7e12
Current standard assays to study hepatotoxicity of drugs
and chemicals use isolated hepatocytes in suspension or in
culture. Although primary human hepatocytes are the most
appropriate in vitro hepatotoxicity and disease model,
availability, donor-to-donor variability, and early phenotype
changes in culture are efﬁcaciously limiting.
Another important consideration for liver disease and drug
toxicity models is immune-mediated responses associatedstigative Pathology.
.with drug metabolites. These responses require interactions
between hepatocytes and liver nonparenchymal cells (eg,
Kupffer cells, endothelial cells, bile duct cells, and stellate
cells).13e15 There is a need for in vitro three-dimensional
(3D) models based on human cells that integrate external
cues, such as those that result from various organ-speciﬁc
extracellular matrix (ECM) components, soluble signals,
mechanical stimulation, and cues from neighboring and
distant tissues/organs.
Liver Engineering to Study Liver DiseaseOrgan-like systems have already been shown to be integral
for the study of the cellular microenvironment, particularly
responses to the perturbation of the microenvironment in
pathological situations, as well as hepatic differentiation of
stem cells.8,9,11,16,17 Organ-like systems based on human cells
may bridge the gap between animal models and human studies,
facilitating the understanding of basic mechanisms of human
disease. Liver organotypic models can be tightly controlled and
are usually less expensive and time-consuming than animal
models, and can be used to assess many different combinations
of experimental parameters. Such high-throughput testing is
often not feasible with animal-based models.
Approaches to liver disease modeling and hepatotoxicity
studies are particularly attractive, because this ﬁeld routinely
makes use of materials that function as ECM analogues to
provide a substrate for cell adhesion and differentiation,
which could be used to promote the assembly of tissues and
organs.18 By integrating progressively complex cell types,
scaffold materials, and culture environments, different as-
pects of organ development have been successfully recapit-
ulated, providing us with valuable information toward the
development of entire transplantable organs. A functional
whole organ liver has not yet been generated, but much
progress has been made toward achieving this goal.
Herein, we highlight promising areas of investigation in
whole organ liver engineering. First, hepatic function,
regeneration, and differentiation are inﬂuenced by the ar-
chitecture of the organ. Efforts using organ bioengineering
technology seek to elucidate how 3D architecture affects
liver function and differentiation. Second, liver function is
not solely controlled by hepatocytes. New research aims to
understand how organ-speciﬁc ECM and different cell types
within the liver coordinate to regulate liver function and
hepatic differentiation of human stem cells. Finally, we
describe the main challenges in translating whole organ liver
engineering into a proven in vitro model that captures the
complex features of the in vivo environment.Figure 1 Structural and cellular cues in 2D and 3D. 2D cultures are
often monocultures (consisting of only one cell type), thus being a rather
poor approximation of tissue in living organisms. The cues encountered by
a cell are dramatically different between an extracellular matrix-coated
plastic surface (2D) and a typical 3D extracellular matrix, such as
collagen- or organ-derived scaffolds. These differences include cellular
morphological features, differentiation, proliferation, apoptosis, and gene
expression. 3D liver cell cultures provide evident advantages for applica-
tions such as in vitro efﬁcacy/toxicity testing for drug discovery or in vivo/
ex vivo growth of tissues for regenerative medicine.3D Tissue Conﬁguration
In liver tissue, as in other tissues, interactions between a cell
and its surroundings are integral for proper cellular function.
In recent years, much cell biological research has become
dynamic and 3D. Traditionally, most studies on hepatocytic
functions have relied on cells grown in two-dimensional
(2D) cell culture models that fail to recapitulate the in vivo
cellular microenvironment; as a result, these cultures fail to
maintain their differentiated functions. The 3D cell culture
models have recently become important for hepatic func-
tional studies because they often induce levels of cell dif-
ferentiation and tissue organization not observed in
conventional 2D culture systems.19e21
Initial efforts toward the development of 3D cell culture
models incorporated liver cells grown within ECM gels (eg,
type I collagen). This approach enhances expression ofThe American Journal of Pathology - ajp.amjpathol.orgdifferentiated functions and improves tissue organization.22
The effect of collagen 3D conﬁguration is best illustrated
when culturing isolated human hepatocytes on a simple
collagen gel. A week-old culture of hepatocytes loses much
of the normal hepatic phenotype23; in contrast, the addition
of a collagen overlay produces a stable, functional pheno-
type of hepatocytes in culture.22 This suggests that there is a
sensitive and dynamic relationship between ECM conﬁgu-
ration and the intracellular events that determine hepatocyte
morphological features and liver-speciﬁc function.
Culturing cells in 3D versus 2D environments also pro-
vides another dimension for external mechanical inputs and
cell adhesion, which dramatically affects synthesis of coag-
ulation factors (factors VII, VIII, and IX and ﬁbrinogen) and
coagulation inhibitors (antithrombin III and protein C) in
human hepatocytes,24 maintains stable cytochrome P450
inducibility long-term in human and rodent hepatocytes,25,26
induces integrin ligation,27 and affects associated intracel-
lular signaling.28 This suggests that 3D platforms provide a
more in vivoelike environment, allowing cells to maintain
their natural phenotype. Elevated hepatic capabilities,
observed most commonly in multicellular spheroid models,
have been attributed to several factors, including differences
in metabolic state and cell cycle arrest at the G0/G1 phase, up-
regulation of genes involved in liver function, and increased
prosurvival signaling (Figure 1).
The generation of decellularized organs provides the
physiological 3D structures of the native organdincluding349
Handa et alvascular conduits, which have so far proved difﬁcult to
manufacture in vitro.29e33 The development of organ-
engineering approaches has opened entirely new possibil-
ities to generate in vitro cell culture models that reconstitute
complex 3D organ-level structures to which crucial dynamic
mechanical cues and chemical signals can be integrated
(Figure 1). For example, this type of model could be used to
study polarized functions of various epithelial cells (eg,
heart,29 lung,30 kidney,34 and liver31,32). Song et al34 recently
incorporated endothelial and epithelial cells into a decellu-
larized kidney ECM scaffold in which the cells were inte-
grated into the interstitial space and the vascular networks.
Similarly, human fetal liver cells have been incorporated into
a decellularized liver model.33 In this manner, natural scaf-
folds can be used to mimic the tissue-tissue interface that is a
crucial element of whole liver organ structure in ways not
previously possible using conventional 3D ECM gel cultures.
Hepatocytes possess two basolateral areas that interface
with the sinusoidal microvasculature on opposite sides of the
multiple cell layers. This conﬁguration establishes a unique
cytoarchitecture in the liver. We just have started to under-
stand the extent to which this unique hepatic cytoarchitecture
affects function, differentiation, and regeneration. For
example, Tanimizu et al35 applied a 3D culture technique to a
liver progenitor cell line and established an in vitro culture
system in which liver progenitors acquired differentiated
cholangiocyte characteristics. The authors designed a spe-
ciﬁc microenvironment to induce cholangiocyte differentia-
tion; histochemical data demonstrated that only when the
liver progenitor cells developed apicobasal polarity with the
luminal space and formed cysts was cholangiocyte differ-
entiation achieved. Within the cysts, F-actin bundles and
atypical protein kinase C were expressed at the apical
membrane, E-cadherin was localized to the lateral mem-
brane, and b-catenin and integrin a-6 were localized to the
basolateral membrane. By using a similar 3D culture tech-
nique, the same authors have more recently found that api-
cobasal polarity and 3D cyst formation are not the only
necessary components for bile duct differentiation and for-
mation. a-1econtaining laminin (a component of the basal
lamina) was also found to play an essential role in apicobasal
polarization and the commitment of bipotential liver pro-
genitors to cholangiocytes, whereas a-5econtaining laminin
is necessary for the formation of mature duct structures.36
To date, efforts to generate hepatocytes from human
pluripotent stem cells have produced immature hepatic
phenotypes.37e42 Applying 3D systems to stem cell differen-
tiation protocols may signiﬁcantly improve hepatocyte matu-
ration and functionality.43e48 Several 3D approaches have
been reported to induce hepatic maturation, and the idea of
using 3D systems for hepatic maturation was recently vali-
dated in cellular aggregates and bioreactors. Ogawa et al45
investigated the mechanisms underlying hepatocyte matura-
tion by introducing 3D aggregation of hepatoblasts, which
initiated a greater maturation of these progenitor cells. The
authors also manipulated speciﬁc signaling pathways at350different stages of hepatocyte development using cyclic
adenosine monophosphate signaling within the hepatoblast
aggregates, which promoted further maturation toward a
hepatocyte-like population that expressed some metabolic
enzymes at levels comparable to those of primary human he-
patocytes. In another approach, Sivertsson et al46 investigated
hepatic differentiation of human embryonic stem cells using a
3D bioreactor system. The authors identiﬁed pathways highly
related to liver function, which were signiﬁcantly up-regulated
in cells differentiated in the bioreactor compared with 2D
control cultures. These results provide new insights into the
pathways regulating hepatocyte maturation from human
pluripotent stem cells, as well as methods for generating
relatively functional hepatocytes for use in drug metabolism
studies and regenerative medicine-based approaches.Organ-Speciﬁc Extracellular Matrix
The ECM of various tissues and organs is composed of the
same groups of molecules and, often, the same individual
components. The respective concentrations, ratios, and as-
sociations of these components are speciﬁc to support
functions such as tissue homeostasis, differentiation, and
repair. Thus, the structure and composition of the ECM
differ from tissue to tissue based on the function that spe-
ciﬁc tissue serves. The unique ECM microstructure and
ultrastructure provide distinct signals for the cells that reside
within the tissue. Hepatic ECM has been extensively studied
because of its importance in hepatic homeostasis. ECM
isolated from liver has been shown to maintain the pheno-
type of hepatocytes or liver sinusoidal endothelial cells in
culture.49,50 ECM has also been implicated as an important
modulator of organogenesis.51
In the liver, as in all organs, collagen is the major structural
framework component of the organ. There is a speciﬁc dis-
tribution and localization of different ECMs in regenerating,
developing, and normal livers. For instance, in fetal and
neonatal liver, laminin, collagen types I, III, and IV, ﬁbro-
nectin, and tenascin are localized in the perisinusoidal space,
laminin and type IV collagen are present in all hepatic base-
ment membranes, and ﬁbronectin are present diffusely in
connective tissues in the subcapsular, perivascular, and portal
regions, integrating the hepatic ECM in the earliest gestational
age (Figure 2). In contrast, in adult liver, laminin expression is
repressed and localized in the sinusoidal vasculature, and only
highly expressed in regenerating livers. The transient expres-
sion of laminin in the perisinusoidal space is a characteristic of
hepatic regeneration and development.51 These early ﬁndings
suggested that the speciﬁc ECM phenotype in the peri-
sinusoidal space is important in modulating hepatic morpho-
genesis (Figure 2). There are also non-structural matricellular
proteins that support cell adhesion, migration, proliferation,
apoptosis, and differentiation.52,53 Together, the ECM and
matricellular proteins control the local mechanical environ-
ment and contribute to the microenvironment through theirajp.amjpathol.org - The American Journal of Pathology
Figure 2 Extracellular matrix expression and distribution human fetal
and adult liver. A: Schematic representation of the expression of hepatic
ECM during liver development. B and C: Laminin (green) in the fetal human
liver of the 12th gestational week (GW) is in the early periportal matrix and
around microvessels. However, laminin distribution in human adult liver is
in the basal membrane of the blood vessels. Type IV collagen (red) in the
fetal human liver of the 12th GW localized mainly in the periportal matrix;
in contrast, human adult liver shows diffuse expression present within the
entire hepatic parenchyma. a-Fetoprotein (AFP) expression is also shown in
fetal human liver of the 12th GW and adult liver. Scale bar Z 50 mm.
Liver Engineering to Study Liver Diseaseown signaling and their ability to bind growth factors, cyto-
kines, enzymes, and other diffusible molecules. Because many
growth factors, chemokines, and other signaling proteins are
secreted in matrix-binding forms (especially sulfate pro-
teoglycans), the presence of heparin sulfate in the matrix al-
lows storage and release of these molecules, such as heparin-
binding angiogenic factors, ﬁbroblast growth factor 2, vascular
endothelial growth factor, and hepatocyte growth factor.54
Therefore, ECM proteins can regulate cell signaling through
canonical interaction with their standard adhesive receptors or
by noncanonical growth factor presentation.
How do cell-ECM contacts affect liver function and dif-
ferentiation? Cell contact with extracellular ligands will induce
integrin activation and the recruitment of intracellular adapter
proteins, leading to speciﬁc cell signaling.55 On binding to the
ECM, integrins cluster on the membrane and form focal ad-
hesions via recruitment and activation of various signaling and
adaptor proteins, such as focal adhesion kinase, the Src family
of kinases, talin, paxillin, a-actinin, tensin, and vinculin.56,57The American Journal of Pathology - ajp.amjpathol.orgOther signaling events mediated by integrins include intra-
cellular Ca2þ concentrations, integrin-linked kinase, and
growth factor signaling pathways, such as RaseRafemi-
togen-activated kinase, protein kinase C, and phosphatidyli-
nositol 3-kinase pathways, depending on the speciﬁcity of
integrin binding.57 Recent published data indicate the role of
certain integrins as mediators of liver disease.57 Surprisingly,
scientiﬁc reports on targeting integrins in experimental models
of organ disease with human liver cells are limited. In this
context, organotypic ex vivo systems using decellularized or-
gans could potentially serve as a model to investigate the
biological features of cell-ECM interactions incorporating a
multicellular approach.
The extent to which ECM interactions with integrins affect
hepatic differentiation of human pluripotent stem cells is a
mystery. Liver-speciﬁc ECM could serve as a guide en route
to liver cells. Current endodermal differentiation strategies
involve guiding pluripotent stem cells through sequential,
staged growth factors and cytokines known to be important in
embryonic signaling. However, the results are often variable
and inefﬁcient, depending on the cell line.42 Brafman et al58
recently reported an ECM-based interaction to guide human
pluripotent stem cells toward deﬁnitive endoderm. The in-
vestigators ﬁrst used a high-throughput combinatorial ECM
protein array platform to identify ﬁbronectin and vitronectin
as components that improve deﬁnitive endoderm differenti-
ation. More important, the authors identiﬁed the integrin re-
ceptors that engage in deﬁnitive endoderm differentiation.
This work demonstrates the utility of investigating ECM-
integrin interactions to improve pluripotent stem cell differ-
entiation. In another approach, Marongiu et al59 used porcine
liver ECM-gel as a substrate for hepatic differentiation of
human amniotic epithelial cells. Interestingly, Matrigel, a
commercial matrix preparation known to enhance and
maintain differentiated adult hepatocytes, was ineffective at
inducing hepatic differentiation of human amniotic epithelial
cells. However, liver-speciﬁc ECM was shown to signiﬁ-
cantly induce expression of mature hepatocyte marker genes
and activities (ammonia and 17-hydroxyprogesterone cap-
roate metabolism and inducible cytochrome P450, family 3,
subfamily A, CYP3A and 1A enzymes).
A major milestone in the establishment of techniques for
massive expansion of human hepatoblasts was the demon-
stration of the role of human laminin-111 facilitating the pu-
riﬁcation and expansion of human-induced pluripotent stem
cellederived hepatoblast-like cells.60 Elegant experiments by
Takayama et al60 addressed the role of human laminin-111, a
key hepatic ECM during liver development. Studies showed
that during human liver development, laminin is observed in
both the perisinusoidal space and portal tracts (Figure 2).51
Human pluripotent stem cells were partially differentiated
into hepatoblast-like cells and cultured on dishes coated with
various types of human recombinant laminins. Human
pluripotent stem cellederived hepatoblasts attached and grew
only on human laminin-111ecoated dishes. These cell pop-
ulationsmaintained hepatocytic markers for the duration of the351
Handa et al3-month study. The authors found that cell attachment and
growth occurred in an integrin a-6e and b-1edependent
manner. These results demonstrated the role of organ-speciﬁc
matrix in mediating the maintenance and expansion of hepatic
progenitors derived from pluripotent stem cells. Cell-
matrixespeciﬁc interactions may represent an interesting
mechanism for enabling ampliﬁcation of hepatic progenitors,
making it a promising approach for generating liver cells for
various medical applications, such as drug screening and
regenerative medicine.
There is an increasingly large body of literature indicating
that liver-speciﬁc gene expression, morphogenesis, and cell
function are promoted by interactions between liver cells
and the surrounding ECM. It is rational to expect that bio-
logical scaffolds derived from decellularized livers would
provide adequate distribution of ECM proteins for cell
differentiation, hence strengthening hepatic maturation.
Altogether, these approaches suggest that the presence of
organ-speciﬁc ECM, combined with growth factors, cyto-
kines, and hormones, is required for differentiation of
pluripotent stem cells into hepatocyte-like cells.Multicellular Liver Organoids
Recently, in an effort to better describe and predict the
phenotypic characteristics of tissue repair, a signiﬁcant
amount of attention has been given to the concept of the liver
microenvironment and the role played by nonparenchymal
cells in liver regeneration.61 Adhesion of epithelial cells to
one another is an important process for the differentiation of
multicellular organisms, and cell-cell interactions are known
to be essential for proper liver function.61e66 Interactions
between cells are necessary to maintain proper parenchymal
phenotype and regulate cellular behavior. Perturbations in the
normal cell-cell interactions, whether environmentally or
intrinsically induced, can affect the ability of a cell to respond
normally to toxic insult of drugs and other xenobiotics.
Although the functional importance of cell-cell interactions is
well established in many tissues, including the liver, the
fundamental molecular mechanisms underlying these in-
teractions are still unclear. Research into cell-cell interactions
is further confounded by the diversity of supportive cell types
present in whole organs. For example, Patel et al62 recently
demonstrated the role of gap junctions in the prevention of
fulminant hepatic failure and acetaminophen-induced hepa-
totoxicity. Studies showed that liver-speciﬁc gap junction
(connexin 32) inhibitors could limit liver injury caused by
hepatotoxic drugs by affecting cell-cell communication.
These results implicate a role for gap junctions in mediating
responses to liver injury. This work demonstrates that cellular
communications between parenchymal cells of the liver may
be a mechanism for enabling ampliﬁcation of injury; how-
ever, the same mechanism has yet to be proved in human
tissue. Thus, development of human organotypic models
may aid in the search for novel therapeutic targets.352Conventional approaches to investigate mechanisms of
cell-cell interactions have included co-cultures of two or
more cell types, involving direct or indirect co-culture, with
heterotypic cell-cell contacts and paracrine signaling.
However, these co-cultures do not mimic the conﬁguration
of a real organ.63,65e69 Early attempts to study cell-cell in-
teractions aided in the understanding of how constituent cell
types interact to achieve liver-speciﬁc structure and func-
tion; the interactions between hepatocytes and endothelial
cells in the formation of vascular structures leading to liver
morphogenesis have been especially well studied.63,66,67,69
Hepatocytes have also been co-cultured with hepatic stel-
late cells,70,71 which have been shown to coexist with he-
patocytes in vivo and participate in cell-cell signaling
necessary for liver regeneration and homeostasis. Rat he-
patocytes co-cultured with rat stellate cells show formation
of hepatic ultrastructure, including bile canaliculi, desmo-
somes, and tight junctions through ECM synthesis, direct
signaling to the hepatocytes, and enhancement of cyto-
chrome P450ecatalyzed metabolism of testosterone. These
studies highlight the importance of stromal cells and culture
conditions in retaining metabolic function and mimicking
liver tissue in vivo.
Isolated hepatocytes have been co-cultured with other
nonparenchymal cells and shown higher levels of meta-
bolism (eg, cytochrome P450) and synthesis (eg, albumin
and urea) as highlighted before. In addition to the supportive
role of other cell types in maintaining hepatic functions, co-
cultures have also been used to study the signaling pathways
involved in inﬂammatory responses to drugs and cytokines
by hepatocytes.13,72 For instance, co-cultures of primary
hepatocytes and Kupffer cells were used to elucidate and
reproduce the effect of inﬂammatory cytokines on cyto-
chrome P450, family 3, subfamily A clearance of drugs
observed in vivo.13 Others72 have used this combination to
study the effect of certain xenobiotic agents known to
induce hepatotoxicity in humans (acetaminophen, chlor-
promazine, allyl alcohol, and monocrotaline) and to analyze
the ability of Kupffer cells to release inﬂammatory media-
tors. Most important, these studies have demonstrated that
hepatocytes not co-cultured with Kupffer cells do not pro-
duce the same effects, suggesting that Kupffer cell activa-
tion and production of inﬂammatory mediators are useful
and necessary to elicit these xenobiotic responses. Data
from these studies qualitatively mirror reported data from
whole animal studies, suggesting that hepatic co-culture
models could be useful for predicting aspects of
xenobiotic-inﬂammation interactions in vivo.
Efforts to provide an alternative source of organs have
shifted away from immunosuppressive regimens and toler-
ance induction toward the need to expand the donor pool
through generation of autologous organs in the laboratory
using pluripotent stem cells.3 Toward this aim, Takebe et al48
generated a method to coax human-induced pluripotent stem
cells, mesenchymal cells, and endothelial cells into 3D
structures for in vitro growth of human liver organoids. Thisajp.amjpathol.org - The American Journal of Pathology
Liver Engineering to Study Liver Diseasewas done with rudimentary vascular conﬁgurations that can
engraft onto other tissues in mice, on which the organoid
vasculature reassembled into a functional organ. The authors’
work builds on previous identiﬁcation of exogenous signals
and cellular domains during organogenesis and liver devel-
opment, known to change or induce cellular programming
(eg, cell migration, growth, or speciﬁcation).73 Paracrine
signaling between mesenchymal cells and hepatic progenitor
cells is known to initiate liver development; although the
mechanisms involved remain somewhat obscure, the authors
were able to generate small versions of human fetal liver
organoids in vitro. These human liver organoids were
engrafted onto the brains of mice using a cranial window to
assess vascular permeability and engraftment. Remarkably,
the liver organoids connected quickly with host vasculature
(within 2 days after implantation). The documentation of
vascular connection at the edges of the implanted liver orga-
noids is a remarkable event demonstrating the importance of
endothelial cells in conjunction with mesenchymal cells to
support permanent angiogenesis.74 In the past, liver paren-
chymal, nonparenchymal, and stromal cells have been used to
achieve a greater hepatic differentiation of pluripotent stem
cells.75e81 However, the resulting cells and tissues were not
able to reconnect and establish a durable extrahepatic organ.
Also, isolated hepatocytes (rat or human) transplanted into
interscapular fat pads of rats survive as vascularized organo-
ids for the life of the animal and respond to partial hepatec-
tomy with further growth, suggesting that vascularization of
transplanted hepatocytes is essential for their long-term
survival.82e84
These elegant studies expand on growing evidence that it
is possible to differentiate pluripotent stem cells into single
cell types and to replicate the complex 3D organ architec-
ture. This strongly supports the emerging concept that
laboratory-grown organs can be used therapeutically in the
near future. These new developments raise the exciting
possibility that 3D organoid structures can be used to hunt
for additional pathways involved in human liver develop-
ment, especially given the difﬁculty in obtaining human
tissue for this purpose. However, more work must be done
before constructing 3D human liver organoids becomes
possible. The major challenge for engineering human liver
for future clinical use as a replacement for a failing organ is
scaling up the techniques used in rodent models. In the
future, a combination of existing approaches in the ﬁeld of
organ assembly using natural liver ECM as scaffolding31,32
for hepatic cells derived from pluripotent stem cells may be
the most efﬁcacious approach to engineer liver organoids.
Applications and Challenges
In the past, much work has been done to develop a system to
culture well-differentiated, metabolically reactive, and syn-
thetically functional hepatocytes long-term in vitro. There
has been signiﬁcant progress toward understanding the in-
teractions and synergism between cell types integratedThe American Journal of Pathology - ajp.amjpathol.orgwithin the liver, including changes and composition of the
liver ECM, cellular zonation, and architecture. Presently,
there is a great necessity to develop organotypic model
systems that mimic normal and diseased human livers with
the purpose to understand physiological exposure to xeno-
biotics and their metabolites and, most important, to un-
derstand the subsequent adaptive cellular responses and
regenerative processes that eventually lead to adverse effects
in humans.
One special area of interest for the development of orga-
notypic model systems is nonalcoholic fatty liver disorders
(NAFLDs), because of a 30% prevalence among Ameri-
cans.85 NAFLD involves the progression of simple liver
steatosis to nonalcoholic steatohepatitis (NASH; one form of
NAFLD), characterized by hepatocyte injury (hepatocyte
ballooning and cell death), inﬂammatory inﬁltration, and/or
collagen deposition (ﬁbrosis).85 NASH is the fourth most
common indication for liver transplantation in the United
States. At this time, the only deﬁnitive treatment for hepatic
failure is whole organ liver transplantation. However, this
treatment is severely limited by the availability of suitable
human donor livers. Ironically, the donor pool is expected to
shrink over time, because liver steatosis in donors commonly
makes them unsuitable for transplantation.86e88 The factors
that promote fat deposition in the liver and the transition from
steatosis to NASH and cirrhosis in humans are unknown.
Moreover, the metabolic capacities of human fatty livers
have been difﬁcult to document. Although animal models
have helped to deﬁne steatosis development as a combination
of multiple factors that contribute to fatty liver formation, the
relative roles of these pathways in humans have not been
conclusively determined, limiting the applicability of new
therapeutic options.
Consequently, the focus of recent efforts has been on the
development of organotypic platforms that allow the as-
sembly and maintenance of liver tissue derived from
pluripotent stem cells. Pluripotent stem cells can potentially
be genetically engineered to carry speciﬁc genetic disrup-
tions previously observed in animal models, then differen-
tiated to target cells affected in various diseases (eg,
NAFLD) to recapitulate the pathological characteristics of
human disease in vitro for disease modeling and the
development of novel drugs or therapies. The impact of a
human stem cell organ-engineering approach could establish
the basis and platform for future sophisticated organ-
engineering techniques incorporating several different cell
types that may ultimately lead to the development of entire
organ systems in vitro to understand human pathobiological
characteristics. Clinically, the ability to engineer liver grafts
has utility far beyond modeling liver steatosis, and could be
used as a tool to accurately predict the metabolism and
toxicity of a compound in normal and diseased human liver
grafts in vitro before exposure to the whole body; this
potentially translates into reduced costs and time in drug
development, and less harmful patient exposure in clinical
trials.353
Handa et alCurrently, themain challengewith determining the suitability
and relevance of the various types of existing organotypic he-
patic culture systems for different types of toxicological appli-
cations has been the lack of consensus on the standardization of
such systems, namelydeﬁnitions and criteria for the following: i)
biological and toxicological parameters, ii) quality control
measures, iii) minimum acceptable levels of basic hepatic
functions (protein synthesis, basal phase 1 and 2 enzyme acti-
vitydespecially if pluripotent stem cellederived liver cells will
be used), and iv) concentration ranges for importantmediators of
chemical-induced stress, such as mitochondria activity and
adenosine-triphosphate production. These criteria would also
need to be compared with those observed in vivo.Signiﬁcance and Future Perspectives
Beyond the potential clinical implications of assembling
whole livers for transplantation, organ assembly for use in
preclinical models has the potential to make an immediate
and substantial impact on a wide variety of therapeutic and
technological developments (Figure 3). These models can
offer complex 3D conﬁgurations in a controlled and scalable
setting, addressing scientiﬁc and ethical concerns associated
with forms of in vivo testing. Future work involving
cell-cell, cell-ECM biological features, and therapeutic ap-
plications of assembled livers will have to incorporate
human cell types into the organoids, as well as developFigure 3 Schematic representation of the regenerative medicine paradigm
technology, cell differentiation, cell therapy principles, and natural liver matrix
transplantation. Drawings are not to scale.
354technical consistency and comparable validation with other
known standards for testing therapeutic strategies (Figure 3).
The liver ECM presents an ideal scaffold for stem cell
differentiation into hepatocytes, as well as cell trans-
plantation. Whole organ assembly could provide models to
study liver development and hepatic maturation processes,
as well as models to study the complex interactions between
parenchymal and nonparenchymal liver cells. Finally, whole
organ liver assembly could be used as an in vitro tool to
accurately predict drug metabolism and toxicity in human
liver grafts, potentially resulting in reduced costs and time in
drug development, as well as reduced exposure to harmful
agents by patients during clinical trials.
Organ-engineering approaches to stem celleniche in-
teractions in decellularized organs may also provide novel in-
sights into the distinct roles of juxtacrine and paracrine
signaling in stem cell fate decisions, because co-cultures in
organ-speciﬁc structures allow for greater control over
interactions between cell types from the same organ. Further-
more, it may be possible to generate entirely autologous organs
requiring little to no immune suppression, given that protocols
for the directed differentiation of human pluripotent stem cells
into liver nonparenchymal cells are available (Figure 3).
Finally, organotypic ex vivo systems, although minimal-
istic, are likely to be of particular importance in the analysis
of liver disease (eg, hepatocarcinoma and NASH), because
mouse models do not always recapitulate the pathophysio-
logical characteristics seen in humans, and hepatocytesof whole liver assembly using human-induced pluripotent stem (iPS) cell
scaffolds to construct multicellular 3D tissue for biological research and
ajp.amjpathol.org - The American Journal of Pathology
Liver Engineering to Study Liver Diseasegrown as monolayers in culture bear little to no resemblance
to cells as they exist in situ.References
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